Medistim ASA (MEDI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Medistim ASA stock NOK 336, price NOK 306, upside +9.8%, quality 90 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range kr 122.83 – kr 351.25 · fair‑value band kr 246.14 – kr 421.98 · the kr 306.00 price screens below the kr 336.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Medistim in your weekly email
Every Wednesday you see whether Medistim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally.
Show moreShow less
The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and ultrasound imaging probes for intraoperative use.
It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.
In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Stock analysis
Medistim ASA (MEDI) currently trades at kr 306.00, while our model-based Fair Value estimate is kr 336.02, so the stock looks roughly fairly valued today (gap 8.9%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 192.78 per share, and 0 of the 26 models we run sit above the kr 306.00 price.
Bear case: the Economic Profit group reads lowest at kr 80.94, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 246.14 (bear) to kr 421.98 (bull), the price of kr 306.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 90/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Medistim ASA reported revenue of 700M NOK in FY2025 versus 418M NOK in FY2021, a compound +13.8%/yr. Reported net income was 159M NOK in FY2025, compounding +15.0%/yr from FY2021.
Key figures
Market cap 5.6B NOK (≈ $592M) Small · P/E ratio 31.4 · P/S ratio 7.03 · EPS (TTM) kr 9.75 · Dividend yield 3.4% · Net margin 22.4% · Return on equity 40.8% · Return on assets (EBIT) 27.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 69% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 10%, MEDI screens cheaper than that median.
Fair Value models
Bearkr 246.14Fair Value kr 336.02Bullkr 421.98
Price kr 306.00 · Upside +9.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+24.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+21.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.0%
Dividend (yield on the price)3.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.0% vs 15.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 28%
2025 sits 53% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about +16.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score90 · Top 25%
Fair Value upside+9.8% · Above median
Profitability
Return on equity (12 months)40.8% · Top 25%
Return on assets24.1% · Top 25%
Net margin (12 months)22.4% · Top 25%
Operating margin (12 months)30.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)25.9% · Top 25%
Dividend yield (12 months)3.4% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)31.4× · Pricier than median
P/B11.94× · Priciest 25%
P/S (12 months)7.03× · Priciest 25%
Price / free cash flow (fiscal year)29.2× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medistim ASA Fair Value". https://www.fairvalue-calculator.com/stock/MEDI
Frequently asked questions
Is Medistim ASA (MEDI) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of kr 336.02 versus a price of kr 306.00, about +10% upside (fairly valued).
What is the fair value of MEDI?
Our model-based fair value for Medistim ASA is kr 336.02 (as of Nov 7, 2026), built from audited fundamentals. The current price: kr 306.00.
What is the quality score of MEDI?
Medistim ASA has a Quality Score of 90/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medistim ASA (MEDI)?
Our model-based price target is the fair value of kr 336.02 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario kr 246.14, optimistic scenario kr 421.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Medistim ASA stock forecast for 2026?
Our models put fair value at kr 336.02, about +10% upside versus a price of kr 306.00 (fairly valued). Cautious scenario kr 246.14, optimistic scenario kr 421.98. The calculation is refreshed regularly with new filings.
What is the revenue of Medistim ASA (MEDI)?
Medistim ASA reported trailing-twelve-month revenue of about 796M NOK (latest available figure, as of Nov 7, 2026).
Does Medistim ASA pay a dividend?
Medistim ASA currently shows a dividend yield of 3.43% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Medistim ASA (MEDI) and when is the ex-dividend date?
Medistim ASA pays a dividend of kr 10.50 per share a year, a dividend yield of 3.4%. The last ex-dividend date was Oct 27, 2026. A dividend has been paid every year since at least 2005. The payout ratio is 108% of earnings. Free cash flow covers the dividend 1.00 times. Our assessment: Payout strained. The dividend exceeds reported earnings (though reported profit is often depressed by one-off charges), and free cash flow only just covers it (or coverage is unknown). Not an emergency, but little room for error.
What growth is priced into Medistim ASA (MEDI)?
For today's price to be fair in a discounted-cash-flow model, Medistim ASA would have to grow free cash flow by +19.1 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.5 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of MEDI use?
Our models discount Medistim ASA at 10.9 %: a base by market capitalisation (small), damped by beta 0.95, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medistim ASA that is +19.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Medistim ASA (MEDI) delivered so far?
Over the past 5 years revenue at Medistim ASA grew +14.5 % a year. The price currently implies free-cash-flow growth of +19.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medistim ASA (MEDI) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Medistim ASA (+19.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medistim ASA (MEDI)?
The free-cash-flow yield on the price is 3.43 %: that much free cash flow Medistim ASA produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medistim ASA (MEDI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medistim ASA it is kr 336.02 per share (as of Nov 7, 2026), against a price of kr 306.00. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Medistim ASA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, MEDI trades below its calculated fair value: price kr 306.00, fair value kr 336.02, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDI?
No. The price is what the market pays today (kr 306.00); the fair value is what the company's own numbers justify (kr 336.02). For Medistim ASA the two are kr 30.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medistim ASA worth?
The market values Medistim ASA at about 5.6B NOK (market capitalisation, as of Nov 7, 2026). Per share that is kr 306.00; our models calculate a fair value of kr 336.02 per share.
What do the bullish and bearish scenarios say about MEDI?
Our models span a range for Medistim ASA: cautious scenario kr 246.14, base kr 336.02, optimistic kr 421.98 per share (as of Nov 7, 2026, price kr 306.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDI?
Medistim ASA trades at a price-to-earnings ratio of 31.4 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 336.02 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 35.6. Other multiples: PEG 2.3, P/B 11.9, P/S 7.0, EV/EBITDA 21.5.
What is the PEG ratio of MEDI?
The PEG ratio of Medistim ASA is 2.35 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Medistim ASA (MEDI)?
Balance-sheet figures for Medistim ASA (as of Nov 7, 2026): return on equity 40.8%. They feed the Quality Score of 90/100, which measures business quality independently of the share price.
How far is MEDI from its 52-week high?
Medistim ASA trades at kr 306.00, about 1% below its 52-week high of kr 308.00 and 69% above the low of kr 181.40 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 336.02 is for.
Which stocks are comparable to Medistim ASA?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medistim ASA stock attractive at the current price?
The data as of Nov 7, 2026: price kr 306.00, calculated fair value kr 336.02 (+10%), Quality Score 90/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDI calculated?
We run Medistim ASA through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 336.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Medistim ASA currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medistim ASA (MEDI)?
The closing price on Nov 6, 2026 was kr 306.00. Our model-based fair value is kr 336.02, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medistim ASA right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Medistim ASA (MEDI) come from?
Earnings per share at Medistim ASA grew +11.6 % a year from 2011 to 2022. Broken into its drivers: revenue per share +6.0 %, EBIT margin +4.4 %, tax rate +1.0 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Medistim ASA
How large is the market capitalisation of Medistim ASA (MEDI)?
The market capitalisation of Medistim ASA is 5.6B NOK (≈ $592M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medistim ASA (MEDI)?
The price-to-sales ratio of Medistim ASA is 7.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medistim ASA (MEDI)?
Earnings per share at Medistim ASA are kr 9.75 (price ÷ EPS = P/E 31.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medistim ASA (MEDI)?
The dividend yield of Medistim ASA is 3.4% (payout 108%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medistim ASA (MEDI)?
The net margin of Medistim ASA is 22.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medistim ASA (MEDI)?
The return on equity (ROE) of Medistim ASA is 40.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medistim ASA (MEDI)?
On an EBIT basis the return on assets of Medistim ASA is 27.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medistim ASA (MEDI)?
The operating margin of Medistim ASA is 30.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medistim ASA (MEDI)?
Revenue at Medistim ASA is growing +25.9% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medistim ASA (MEDI)?
Earnings per share at Medistim ASA are growing +21.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Medistim ASA (MEDI) hold?
Medistim ASA holds more cash than debt, 101M NOK net (fiscal year 2021). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Medistim ASA in the live analysis
One click puts Medistim ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026